Prepared by R.R. Donnelley Financial -- Common Stock Purchase Agreement dated February 26, 2004


 Exhibit 10.1 
  
 COMMON STOCK PURCHASE AGREEMENT 
  
 DATED AS OF FEBRUARY 26, 2004 
  

BY AND BETWEEN 
  
 CV THERAPEUTICS, INC. 
  
 AND 
  
 MAINFIELD ENTERPRISES, INC. 
  







					
	 ARTICLE I. DEFINITIONS
	  	1
			
	         Section 1.1
	  	Definitions	  	1
		
	 ARTICLE II. PURCHASE AND SALE OF COMMON STOCK; DELIVERY OF SHARES
	  	2
			
	         Section 2.1
	  	Purchase and Sale of Common Stock	  	2
	         Section 2.2
	  	Delivery of the Shares	  	2
		
	 ARTICLE III. REPRESENTATIONS AND WARRANTIES
	  	2
			
	         Section 3.1
	  	Representations and Warranties of the Company	  	2
	         Section 3.2
	  	Representatives and Warranties of the Purchaser	  	6
		
	 ARTICLE IV. COVENANTS
	  	7
			
	         Section 4.1
	  	Compliance with Laws	  	7
	         Section 4.2
	  	Listing	  	8
	         Section 4.3
	  	Disclosure of Material Non–Public Information	  	8
	         Section 4.4
	  	Subsequent Placements	  	8
		
	 ARTICLE V. CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES
	  	8
			
	         Section 5.1
	  	Conditions Precedent to the Obligation of the Company to Sell the Shares	  	8
	         Section 5.2
	  	Conditions Precedent to the Obligation of the Purchaser To Purchase the Shares	  	9
		
	 ARTICLE VI. INDEMNIFICATION
	  	10
			
	         Section 6.1
	  	General Indemnity	  	10
	         Section 6.2
	  	Indemnification Procedures	  	11
		
	 ARTICLE VII. MISCELLANEOUS
	  	12
			
	         Section 7.1
	  	Fees and Expenses	  	12
	         Section 7.2
	  	Specific Enforcement	  	12
	         Section 7.3
	  	Entire Agreement; Amendment	  	12
	         Section 7.4
	  	Notices	  	13
	         Section 7.5
	  	Waivers	  	14
	         Section 7.6
	  	Headings	  	14
	         Section 7.7
	  	Successors and Assigns	  	14
	         Section 7.8
	  	Governing Law; Jurisdiction and Venue	  	14
	         Section 7.9
	  	Survival	  	14
	         Section 7.10
	  	Counterparts	  	14
	         Section 7.11
	  	Publicity	  	15
	         Section 7.12
	  	Severability	  	15
	         Section 7.13
	  	Replacement of Shares	  	15
	         Section 7.14
	  	Further Assurances	  	15

  






 COMMON STOCK PURCHASE AGREEMENT 
  
 This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of February 26, 2004, is made by
and between CV Therapeutics, Inc., a Delaware corporation (the “Company”) and Mainfield Enterprises, Inc., a corporation existing under the laws of the British Virgin Islands (the “Purchaser”). 
  
 RECITALS 
  
 WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall
issue and sell to the Purchaser and the Purchaser shall purchase 1,609,186 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”). 
  
 NOW, THEREFORE, the parties hereto agree as follows: 
  
 AGREEMENT 
  
 ARTICLE I. 
 DEFINITIONS

  
 Section 1.1 Definitions 

 
 (a) “Commission” shall mean the
Securities and Exchange Commission or any successor entity. 
  
 (b) “Commission Documents” shall mean all reports, schedules, forms, statements and other documents filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act,
including material filed pursuant to Section 13(a) or 15(d) of the Exchange Act, which have been previously filed by the Company, including, without limitation the Form 10-K filed by the Company for the year ended December 31, 2002 (the
“2002 Form 10-K”), and shall include all information contained in such filings and all filings incorporated by reference therein. 
  
 (c) “Commission Filings” means the Registration Statement, as the same may be amended from time to time, the Prospectus,
and all other filings relating to the sale of the Shares hereby made by the Company with the Commission prior to or after the date hereof pursuant to the Exchange Act. 
  
 (d) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the
rules and regulations of the Commission thereunder. 
  
 (e) “GAAP” shall mean generally accepted accounting principles in the United States of America. 






 (f) “Material Adverse Effect” shall mean (i) any effect on the business,
operations, properties or financial condition of the Company that is material and adverse to the Company and its Subsidiary and affiliates, taken as a whole, (ii) any condition, circumstance, or situation that could prohibit or otherwise materially
interfere with the ability of the Company to enter into and perform any of its obligations under this Agreement in any material respect or (iii) any condition, circumstance, or situation that could affect the legality, validity or enforceability of
this Agreement. 
  
 (g) “Nasdaq”
means the Nasdaq National Market or any successor thereto. 
  
 (h) “Prospectus” as used in this Agreement means the prospectus in the form to be included in a filing with the Commission pursuant to Rule 424(b) promulgated under Securities Act, including the
supplement thereto relating to the sale of the Shares hereby. 
  
 (i) “Registration Statement” shall mean the registration statements on Form S-3, Commission File Number 333-109428 and Commission File Number 333-53202, under the Securities Act, filed by the Company
with the Commission, as such Registration Statement may be amended from time to time. 
  
 (j) “Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission
thereunder. 
  
 ARTICLE II. 
 PURCHASE AND SALE OF COMMON STOCK; DELIVERY OF SHARES 
  
 Section 2.1 Purchase and Sale of Common Stock. On the basis of the representations, warranties and agreements herein
contained, and upon the terms and subject to the conditions herein set forth, the Company agrees to issue and sell 1,609,186 shares of Common Stock (the “Shares”) to Purchaser, and the Purchaser agrees to purchase the Shares from
the Company. The purchase price for each Share shall be $15.5358 per share, for an aggregate purchase price of $24,999,991.86 (the “Purchase Price”). 
  
 Section 2.2 Delivery of the Shares. The closing of the sale of the Shares (the
“Closing”) shall take place at the offices of Proskauer Rose LLP, 1585 Broadway, New York, New York 10036, on March 2, 2004 or on such other date or at such other location as the parties shall otherwise agree. The date of the
Closing is hereinafter referred to as the “Closing Date.” At the Closing: (x) the Company shall issue and deliver to the Purchaser (i) a stock certificate, registered in the name of the Purchaser and free of all restrictive legends,
representing the Shares or, if Purchaser provides the necessary account information to the Company, the Company shall issue and deliver such Shares in a balance account with The Depository Trust Company through its Deposit Withdrawal Agent
Commission System, (ii)the Prospectus, (iii) confirmation of the filing of the Prospectus, and (iv) the legal opinions of the Company’s outside counsel in the form of Exhibit A; and (y) the Purchaser shall deliver to the Company
an amount equal to the Purchase Price, in immediately available funds by wire transfer to an account designated in writing by the Company for such purpose. 
  
 ARTICLE III. 
 REPRESENTATIONS AND
WARRANTIES 
  
 Section 3.1 Representations and
Warranties of the Company. The Company hereby represents and warrants to the Purchaser that as of the date hereof: 
  

 2 







 (a) Organization and Good Standing. The Company is a corporation duly
incorporated, validly existing and in good standing under the laws of Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. The Company is duly
qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary except for any jurisdiction in which the failure
to be so qualified will not have a Material Adverse Effect. 
  
 (b) Power, Authorization and Enforcement. The Company has the requisite corporate power and authority to enter into and perform this Agreement and to issue and sell the Shares in accordance with the
terms hereof. The execution, delivery and performance of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action, and no further consent
or authorization of the Company is required. This Agreement has been duly executed and delivered by the Company. This Agreement constitutes, or shall constitute when executed and delivered, a valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting
generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 
  
 (c) Subsidiaries. Except for CV Therapeutics Europe Limited (“Subsidiary”), the Company does not
directly or indirectly control or own any interest in any other corporation, partnership, joint venture or other business association or entity. The Company owns, directly or indirectly, all of the capital stock of the Subsidiary free and clear of
any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction (collectively, “Liens”), and all the issued and outstanding shares of capital stock of the Subsidiary are validly issued and are
fully paid, non-assessable and free of preemptive and similar rights. The Subsidiary does not constitute a “significant subsidiary” as defined in Rule 1-02 of Regulation S-X. 
  
 (d) Capitalization. The authorized capital stock of the Company as of the date hereof is set
forth in the Commission Documents or the Commission Filings. As of the date hereof, 29,870,829 shares of Common Stock are issued and outstanding. All of the outstanding shares of Common Stock have been duly and validly authorized, and are fully paid
and nonassessable. Except as set forth in the Commission Documents or Commission Filings, no shares of Common Stock are entitled to preemptive rights or registration rights and there are no outstanding options, warrants, scrip, rights to subscribe
to, call or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company (except for options issued from time to time pursuant to the Company’s stock option plans, not
exceeding the number of shares reserved as set forth in the Commission Documents). Furthermore, except as set forth in the Commission Documents, Commission Filings or in this Agreement, there are no contracts, commitments, understandings, or
arrangements by which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, securities or rights convertible into shares of capital stock of the Company. Except 
  

 3 







 for customary transfer restrictions contained in agreements entered into by the Company in order to sell
restricted securities, the Company is not a party to, and it has no knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. The offer and sale of all capital stock, convertible securities,
rights, warrants, or options of the Company issued prior to the date hereof complied with all applicable federal and state securities laws, and no stockholder has a right of rescission or damages with respect thereto which would have a Material
Adverse Effect. The Company has furnished or made available to the Purchaser true and correct copies of the Company’s Certificate of Incorporation as in effect on the date hereof (the “Articles”), and the Company’s Bylaws
as in effect on the date hereof (the “Bylaws”). 
  
 (e) Issuance of Shares. The Shares to be issued under this Agreement have been duly authorized by all necessary corporate action and, when paid for or issued in accordance with the terms hereof, the
Shares shall be validly issued and outstanding, fully paid and nonassessable, free and clear of all Liens, and the Purchaser shall be entitled to all rights accorded to a holder of Common Stock. The Company has reserved a sufficient number of duly
authorized shares of Common Stock to issue the Shares. At the Closing, the Common Stock is approved for inclusion in the Nasdaq. 
  
 (f) No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the
Company of the transactions contemplated herein do not (i) violate any provision of the Company’s Articles or Bylaws, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Company is a
party (except such rights of termination as have been disclosed to Purchaser, which rights shall have been waived prior to the date hereof), (iii) create or impose a Lien on any property of the Company under any agreement or any commitment to which
the Company is a party or by which the Company is bound or by which any of its respective properties or assets are bound, or (iv) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree
(including federal and state securities laws and regulations) applicable to the Company or its Subsidiary or by which any property or asset of the Company or its Subsidiary are bound or affected, except, in the case of each of clauses (ii), (iii)
and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect. The Company is not required under federal, state or local
law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement, or issue
and sell the Shares to the Purchaser in accordance with the terms hereof (other than any filings which may be required to be made by the Company with the Commission or Nasdaq subsequent to the date hereof, including but not limited to the
Registration Statement and Prospectus which has been or may be filed pursuant hereto); provided, however, that, for purposes of the representation made in this sentence, the Company is assuming and relying upon the accuracy of the
representations, warranties and agreements of the Purchaser herein. 
  

 4 







 (g) Commission Documents, Financial Statements. The Common Stock is
registered pursuant to Section 12(b) or 12(g) of the Exchange Act and the Company has timely filed all Commission Documents. The Company has made available to the Purchaser true and complete copies of the Commission Documents filed with the
Commission since December 31, 2002 and prior to the date hereof. As of their respective dates of filing, the Commission Documents complied in all material respects with the requirements of the Exchange Act and other federal, state and local laws,
rules and regulations applicable to them, and, as of their respective dates of filing, such Commission Documents did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the Commission Documents comply as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the Commission or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with GAAP applied on a consistent basis
during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary
statements), and fairly present in all material respects the financial position of the Company and its Subsidiary as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited
statements, to normal year-end audit adjustments). 
  
 (h) Registration Statement. The Company has prepared and filed with the Commission in accordance with the provisions of the Securities Act, the Registration Statement, which was declared effective by the Commission on or
before February 5, 2004. The Registration Statement is effective on the date hereof and the Company has not received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement or that the
Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends or has threatened in writing to do so. The Registration Statement (including the information or documents
incorporated by reference therein), as of the time it was declared effective, and any amendments or supplements thereto, each as of the time of filing, did not contain any untrue statement of material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading. The issuance of the Shares to the Purchaser is registered by the Registration Statement. 
  
 (i) No Undisclosed Events or Circumstances. No event or circumstance has occurred or exists
with respect to the Company or its Subsidiary or their respective businesses, properties, prospects, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but
which has not been so publicly announced or disclosed, except for events or circumstances which, individually or in the aggregate, do not or would not have a Material Adverse Effect. 
  
 (j) Listing and Maintenance Requirements. The Company has not, in the two years
preceding the date hereof, received notice from the Nasdaq to the effect that the Company is not in compliance with the listing or maintenance requirements thereof. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with the listing and maintenance requirements for continued quotation of the Common Stock on the Nasdaq. The issuance and sale of the Shares hereunder does not conflict with or violate any applicable rules or
regulations of Nasdaq. 
  

 5 







 (k) Certain Fees. Except for the fee payable by the Company to
Lehman Brothers Inc., no brokers, finders or financial advisory fees or commissions will be payable by the Company with respect to the transactions contemplated by this Agreement. The Purchaser shall have no obligation with respect to any fees
incurred by the Company. 
  
 (l) No
Stabilization or Manipulation. Neither the Company nor any of its officers or directors has taken, directly or indirectly, any action designed to cause or to result in, or that has constituted or might reasonably be expected to constitute,
the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. 
  
 (m) Disclosure. The Company confirms that neither it nor its officers or directors has provided the Purchaser or its
agents or counsel with any information that constitutes or might constitute material, nonpublic information, other than the existence of discussions with the Purchaser regarding this Agreement and the transactions contemplated hereby. The Company
understands and confirms that the Purchaser will rely on the foregoing representations in effecting transactions in securities of the Company. The Company acknowledges and agrees that the Purchaser does not make or has not made any oral
representations or warranties with respect to the transactions contemplated hereby. 
  
 (n) Acknowledgment Regarding Purchaser’s Purchase of Shares. The Company acknowledges and agrees that the Purchaser is
acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated hereunder. The Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereunder and any advice given by the Purchaser or any of its representatives or agents in connection with this Agreement and the transactions
contemplated hereunder is merely incidental to the Purchaser’s purchase of the Shares. 
  
 Section 3.2 Representatives and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that, as of the date hereof: 
  
 (a) Organization and Good Standing. The
Purchaser is a corporation, duly incorporated, validly existing and in good standing under the laws of British Virgin Islands. 
  
 (b) Power, Authorization and Enforcement. The Purchaser has the requisite corporate power and authority to enter into and
perform this Agreement and to purchase the Shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by the Purchaser and the consummation by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action, and no further consent or authorization of the Purchaser is required. This Agreement has been duly executed and delivered by the Purchaser. This Agreement constitutes, or shall constitute when executed
and delivered, a valid and binding obligation of the Purchaser enforceable against the Purchaser in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation, conservatorship, receivership, or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 
  

 6 







 (c) Purchaser Holdings. Immediately after the sale of the Shares pursuant
to this Agreement, the Purchaser will not, directly or indirectly, own more than 9.99% of the then issued and outstanding shares of Common Stock. 
  
 (d) Disclosure of Information. The Purchaser has received the Commission Documents and Commission Filings, including,
without limitation, the following: 
  
 (i) the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2002, including information specifically incorporated by reference into Form 10-K from the Company’s definitive proxy statement for its 2003 Annual Meeting of
Stockholders; 
  
 (ii) the Company’s
Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2003, June 30, 2003 and September 30, 2003; 
  
 (iii) the Company’s Current Reports on Form 8-K, filed with the Securities and Exchange Commission on January 3, 2003, January 21,
2003, January 31, 2003, February 19, 2003, March 5, 2003, March 18, 2003, March 24, 2003, April 1, 2003, April 8, 2003, April 16, 2003, May 16, 2003, June 13, 2003, July 3, 2003, July 8, 2003, July 11, 2003, July 17, 2003, August 4, 2003, August 11,
2003, September 17, 2003, October 17, 2003, October 23, 2003, October 29, 2003, October 31, 2003, December 10, 2003, January 22, 2004, January 29, 2004, February 10, 2004 and February 13, 2004; 
  
 (iv) the description of the Common Stock contained in the
Company’s Registration Statement on Form 8-A (File No. 000-21643), filed with the Commission on October 30, 1996; and 
  
 (v) the Registration Statement. 
  
 (e) Certain Fees. The Company shall have no obligation with respect to any fees incurred by the Purchaser. It being
understood that the fee payable to Lehman Brothers Inc. was incurred by the Company. 
  
 ARTICLE IV. 
 COVENANTS 
  
 The Company covenants with the Purchaser, and the Purchaser covenants with the Company, as follows, which covenants of one
party are for the benefit of the other party: 
  
 Section 4.1
Compliance with Laws. The Company and the Purchaser shall comply with all applicable laws, rules, regulations and orders in connection with this Agreement and the transactions contemplated hereby. Without limiting the
foregoing, the Purchaser shall comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, its prospectus delivery obligations with respect to any subsequent resales of the Shares and Regulation M under
the Exchange Act and Exchange Act Rule 13d-1. 
  

 7 







 Section 4.2 Listing. The Company will use its best efforts to
effect and maintain the quotation of the Common Stock on the Nasdaq. 
  
 Section 4.3 Disclosure of Material Non-Public Information. The Company shall not, and shall cause each of its officers and directors not to, divulge to the Purchaser any information that the Company
believes to be material, non-public information, other than the existence of discussions with the Purchaser regarding this Agreement and the transactions contemplated hereby, unless the Purchaser has agreed in writing to receive such information
prior to such divulgence. 
  
 Section 4.4 Subsequent
Placements. From the date hereof until 30 calendar days after the Closing Date, the Company will not without the prior written consent of the Purchaser, directly or indirectly, offer, sell, grant any option to purchase, or
otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or the Subsidiary’s equity or equity equivalent securities, including without limitation any debt, preferred stock or other
instrument or security that is, at any time during its life and under any circumstances, convertible into or exchangeable or exercisable for Common Stock, except (i) options granted under the Company’s stock option plans or shareholder
rights plan and the issuance of shares of Common Stock upon the exercise thereof, (ii) shares of Common Stock issued under the Company’s employee stock purchase plans, (iii) shares of Common Stock issuable upon conversion of options or
convertible securities issued on or prior to the date hereof (provided that such exercise or conversion occurs in accordance with the terms thereof, without amendment or modification of the terms of such securities after the date of this Agreement),
and (iv) shares of Common Stock and/or warrants to purchase shares of Common Stock issued for the purposes of licensing agreements, corporate partnering agreements and/or collaborative agreements with third parties, the primary purpose of which is
not to raise cash, and the issuance of shares of Common Stock upon the exercise thereof. 
  
 ARTICLE V. 
 CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES 
  
 Section 5.1 Conditions Precedent to the Obligation of the
Company to Sell the Shares. The obligation hereunder of the Company to issue and sell the Shares to the Purchaser is subject to the satisfaction or waiver of each of the conditions set forth below. These conditions are for the
Company’s sole benefit and may be waived by the Company at any time in its sole discretion. 
  
 (a) Accuracy of the Purchaser’s Representations and Warranties. The representations and warranties of the Purchaser in
this Agreement shall be true and correct as of the date when made and as of the Closing Date as though made at that time. 
  
 (b) Registration Statement. The Registration Statement shall be effective and there shall be no threatened or actual stop
order suspending effectiveness of the Registration Statement. 
  
 (c) Prospectus. The Prospectus shall have been filed with the Commission. 
  

 8 







 (d) Performance by the Purchaser. The Purchaser shall have performed,
satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date. 
  
 (e) No Injunction. No statute, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this
Agreement. 
  
 (f) No Suspension.
Trading in the Common Stock shall not have been suspended by the Commission or the Nasdaq, and trading in securities generally as reported on Nasdaq shall not have been suspended or limited, nor shall a banking moratorium have been declared either
by the United States or New York State authorities, nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity or crisis of such magnitude in its effect on, or any material adverse
change in, any financial market which, in each case, in the reasonable judgment of the Company, makes it impracticable or inadvisable to issue the Shares. 
  
 (g) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any governmental authority shall
have been commenced, and no investigation by any governmental authority shall have been threatened, against the Company or any of the officers, directors or affiliates of the Company seeking to restrain, prevent or change the transactions
contemplated by this Agreement, or seeking damages in connection with such transactions. 
  
 Section 5.2 Conditions Precedent to the Obligation of the Purchaser To Purchase the Shares. The obligation hereunder of the Purchaser to acquire and pay for the Shares is subject to the
satisfaction or waiver, at or before the Closing Date, of each of the conditions set forth below. The conditions are for the Purchaser’s sole benefit and may be waived by the Purchaser at any time in its sole discretion. 
  
 (a) Accuracy of the Company’s Representations and
Warranties. Each of the representations and warranties of the Company shall be true and correct as of the date when made and as of the Closing Date as though made at that time. 
  
 (b) Registration Statement. The Registration Statement shall be effective and there shall be
no threatened or actual stop order suspending effectiveness of the Registration Statement. 
  
 (c) Prospectus. The Prospectus shall have been filed with the Commission. 
  
 (d) Performance by the Company. The Company
shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. 
  
 (e) No Injunction. No statute, rule,
regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions
contemplated by this Agreement. 
  

 9 







 (f) No Suspension. Trading in the Common Stock shall not have been
suspended by the Commission or the Nasdaq, and trading in securities generally as reported on Nasdaq shall not have been suspended or limited, nor shall a banking moratorium have been declared either by the United States or New York State
authorities, nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity or crisis of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of the Purchaser, makes it impracticable or inadvisable to purchase the Shares. 
  
 (g) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any governmental authority shall
have been commenced, and no investigation by any governmental authority shall have been threatened, against the Company or its Subsidiary, or any of the officers, directors or affiliates of the Company or its Subsidiary seeking to restrain, prevent
or change the transactions contemplated by this Agreement, or seeking damages in connection with such transactions. 
  
 (h) Legal Opinion of Latham & Watkins LLP. The Purchaser shall have received from Latham & Watkins LLP, counsel for
the Company, the opinions, dated as of the Closing Date, in substantially the form of Exhibit A. 
  
 ARTICLE VI. 
 INDEMNIFICATION 
  
 Section 6.1 General Indemnity. 
  
 (a) Indemnification by the Company. The Company
will indemnify and hold harmless the Purchaser and any of its affiliates or any officer, director, partner, controlling person, employee or agent of the Purchaser or any of its affiliates (each, a “Related Person”) for reasonable
legal and other expenses (including the costs of any investigation, preparation and travel) and for any and all losses, claims, damages, liabilities, settlement costs and expenses, including without limitation costs of preparation of legal action
and reasonable attorneys’ fees (collectively, “Losses”) incurred in connection with any action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a
disposition), whether commenced or threatened (each, a “Proceeding”), insofar as such Losses (i) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the Registration
Statement or the Prospectus, or arise out of or are based upon the omission or alleged omission to state in the Registration Statement or the Prospectus a material fact required to be stated therein or necessary to make the statements in the
Registration Statement or the Prospectus, in light of the circumstances under which they were made, not misleading, as such Losses are incurred or (ii) relate to any breach by the Company of any of the representations, warranties or covenants made
by the Company in this Agreement, or any allegation by a third party that, if true, would constitute such a breach. The conduct of any Proceeding for which indemnification is available under this Section 6.1(a) shall be governed by Section 6.2.

  

 10 







 (b) Indemnification by the Purchaser. The Purchaser will indemnify and hold
harmless the Company, each of its directors, officers, employees and agents, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act from and against any Losses
(including reasonable costs of defense and investigation and all attorneys fees) to which the Company, each of its directors, officers, employees and agents and each such controlling person may become subject, under the Securities Act or otherwise,
to the extent (and only to the extent) such Losses (or actions in respect thereof), as incurred, arise out of (i) an untrue statement or omission, included in any Prospectus or Prospectus supplement or any amendment or supplement to the Prospectus
or Prospectus supplement in reliance upon, and in conformity with, written information furnished by the Purchaser to the Company for inclusion in the Prospectus or Prospectus supplement, or (ii) an omission to state in any Prospectus or Prospectus
supplement or any amendment or supplement to it a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, the untrue statement or omission was made
in reliance upon, and in conformity with, written information furnished by the Purchaser to the Company for inclusion in the Prospectus or Prospectus supplement or an amendment or supplement to it. The Purchaser hereby confirms that the proposed
plan of distribution as set forth in Exhibit B hereto shall constitute written information furnished by the Purchaser to the Company for inclusion in the Prospectus or Prospectus supplement or an amendment or supplement to it. The conduct of
any Proceeding for which indemnification is available under this Section 6.1(b) shall be governed by Section 6.2. 
  
 (c) The Company’s obligation to indemnify Purchaser, and Purchaser’s obligation to indemnify the Company, shall not limit any
other rights, including without limitation rights of contribution which either party may have under statute or common law. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party
in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys fees and other reasonable costs and expenses incurred with the investigation, preparation, prosecution, collection and enforcement of such action or
proceeding. 
  
 Section 6.2 Indemnification
Procedures. 
  
 (a) If any
Proceeding shall be brought or asserted against any person entitled to indemnity hereunder (each, an “Indemnified Party”), such Indemnified Party shall promptly notify the person from whom indemnity is sought (the
“Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in
connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent
that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have prejudiced the Indemnifying Party. 
  
 (b) An Indemnified Party shall have the right to employ
separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying 
  

 11 







 Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have
failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both
such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel in writing (with a copy to the Indemnifying Party) that a material conflict of interest is likely to exist if the same counsel were to
represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying
Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any Proceeding without its written consent, which
consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such
settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding and does not impose any monetary or other obligation or restriction on the Indemnified Party.

  
 (c) All reasonable fees and expenses of the
Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Article VI) shall be paid to the Indemnified Party, as
incurred, within fifteen business days of written notice thereof to the Indemnifying Party, which notice shall be delivered no more frequently than on a monthly basis (regardless of whether it is ultimately determined that an Indemnified Party is
not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified
Party is not entitled to indemnification hereunder). 
  
 ARTICLE
VII. 
 MISCELLANEOUS 
  
 Section 7.1 Fees and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by
this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the issuance of the Shares. 
  
 Section 7.2 Specific Enforcement. The Company and the Purchaser acknowledge and agree that irreparable damage would occur in
the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either party shall be entitled to an injunction or injunctions to prevent or
cure breaches of the provisions of this Agreement by the other party and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which either party may be entitled by law or equity. 
  
 Section 7.3 Entire Agreement; Amendment. This
Agreement represents the entire agreement of the parties with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by either party relative to subject matter hereof not expressly set forth
herein. No provision of this Agreement may be amended other than by a written instrument signed by both parties hereto. 
  

 12 







 Section 7.4 Notices. Any notice, demand, request, waiver or other
communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand delivery, by telex (with correct answer back received), telecopy or facsimile (with telecopy or facsimile machine confirmation of
delivery received) at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business
day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing,
whichever shall first occur. The address for such communications shall be: 
  

			
		
	If to the Company:	  	 CV Therapeutics, Inc.
 3172 Porter Drive
 Palo Alto, CA 94304
 Telephone Number: (650) 384-8611
 Fax: (650) 858-0388
 Attention:        Tricia Borga Suvari
 Vice President and General
Counsel

		
	With copies to:	  	 Latham & Watkins LLP
 135 Commonwealth
Drive
 Menlo Park, CA 94025
 Telephone Number: (650)
328-4600
 Fax: (650) 463-2600
 Attention: William C. Davisson,
III, Esq.

		
	If to the Purchaser:	  	 Mainfield Enterprises, Inc.
 c/o Sage Capital Growth,
Inc.
 660 Madison Avenue
 New York, NY 10022
 Telephone No.: (212) 651-9000
 Facsimile No.: (212) 651-9010
 Attn: Eldad Gal

		
	With copies to:	  	 Proskauer Rose LLP
 1585 Broadway
 New York, New York 10036-8299
 Facsimile No.: (212) 969-2900
 Telephone No.: (212) 969-3000
 Attn: Adam J. Kansler,
Esq.


  
 Either party hereto
may from time to time change its address for notices by giving at least ten (10) days advance written notice of such changed address to the other party hereto. 
  

 13 







 Section 7.5 Waivers. No waiver by either party of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provisions, condition or requirement hereof, nor shall any delay or omission of any party to exercise any
right hereunder in any manner impair the exercise of any such right accruing to it thereafter. No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought.

  
 Section 7.6 Headings. The article,
section and subsection headings in this Agreement are for convenience only and shall not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. 
  
 Section 7.7 Successors and Assigns. The Purchaser
may not assign this Agreement to any person without the prior written consent of the Company, in the Company’s sole discretion; provided, however, that after the Closing the Purchaser may assign this Agreement to any affiliate of
the Purchaser without the prior consent of the Company. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. The assignment by a party to this Agreement of any rights hereunder shall not
affect the obligations of such party under this Agreement. No other person shall have any right, benefit or obligation under this Agreement as a third party beneficiary or otherwise. 
  
 Section 7.8 Governing Law; Jurisdiction and Venue. All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees
that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees
or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Agreement), and
hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court. Each party hereto hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. 
  
 Section 7.9 Survival. The representations and
warranties of the Company and the Purchaser contained in Article III and the covenants contained in Article IV shall survive the execution and delivery hereof. 
  

Section 7.10 Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall
constitute one and the same instrument and shall become effective when counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties need not sign the same counterpart. In the event any
signature is delivered by facsimile transmission, the party using such means of delivery shall cause four additional executed signature pages to be physically delivered to the other parties within five days of the execution and delivery hereof.

  

 14 







 Section 7.11 Publicity. Neither the Company nor the Purchaser shall issue any
press release or make any other public announcement relating to this Agreement unless (i) the content thereof is mutually agreed to by the Company and the Purchaser, or (ii) such party is advised by its counsel that such press release or public
announcement is required by law, regulation or Nasdaq. The Company shall (i) on or before 9:30 a.m (New York time) on February 27, 2004, file the Prospectus with the Commission, disclosing the transactions contemplated hereby and (ii) on or before
the Closing Date, the Company shall file a Current Report on Form 8-K with the Commission describing the terms of the transactions contemplated by this Agreement and including this Agreement as an exhibit to such Current Report on Form 8-K, in the
form required by the Exchange Act. 
  
 Section 7.12
Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one or more of the provisions or part of the provisions contained in this
Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement, and this Agreement shall
be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent possible. 

 
 Section 7.13 Replacement of Shares. If any
certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new
certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity or surety bond, if requested. The applicants for a new certificate or
instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Shares. 
  
 Section 7.14 Further Assurances. From and after the date of this Agreement, upon the request of the Purchaser or the Company,
each of the Company and the Purchaser shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

  
 [Signature Page Follows] 
  
  

 15 







 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officer as of the date first above written. 
  

			
	CV THERAPEUTICS, INC.
		
	 By:
	 	 /s/    LOUIS G. LANGE


	 	 	 Name: Louis G. Lange, M.D., Ph.D.
 Title: Chairman and
Chief Executive Officer



  

			
	MAINFIELD ENTERPRISES, INC
		
	 By:
	 	 /s/    AVI VIGDER


	 	 	 Name: Avi Vigder
 Title: Authorized
Signatory



  
  






 EXHIBIT A 
  
 FORM OF LEGAL OPINION 
  
 1. The Company is a corporation under the General Corporation Law of the State of Delaware with corporate power and authority to own its properties and to
conduct its business as described in the Registration Statement and the Prospectus. Based on certificates from public officials, we confirm that the Company is validly existing and in good standing under the laws of the State of Delaware and is
qualified to do business in California. 
  
 2. The Shares to be
issued and sold by the Company pursuant to the Purchase Agreement have been duly authorized by all necessary corporate action of the Company and, when issued to and paid for by you in accordance with the terms of the Purchase Agreement, will be
validly issued, fully paid and non-assessable and free of preemptive rights arising from the Certificate of Incorporation or Bylaws of the Company. 
  
 3. The execution, delivery and performance of the Purchase Agreement have been duly authorized by all necessary corporate action of the Company, and the
Purchase Agreement has been duly executed and delivered by the Company. 
  
 4. The Registration Statement has become effective under the Securities Act. With your consent, based solely on a telephonic confirmation by a member of the Staff of the Commission on
                    , 2004, no stop order suspending the effectiveness of the Registration Statement has been issued under the Act and no proceedings
therefor have been initiated by the Commission. 
  
 Such opinions
shall be subject to customary limitations, qualifications and exceptions. In rendering such opinions, Latham & Watkins LLP may rely as to matters of fact (but not as to legal conclusions), to the extent they deem proper, on certificates of
responsible officers of the Company and public officials. The final opinion letter is subject to the review of the opinion committee of Latham & Watkins LLP. 






 EXHIBIT B 
  
 PLAN OF DISTRIBUTION INSERT 
  
 Mainfield Enterprises and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be
“underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act. Mainfield Enterprises does not expect these commissions and discounts to exceed what is customary in the types of transactions involved. Discounts, concessions,
commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by Mainfield Enterprises. Mainfield Enterprises may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving
sales of the shares if liabilities are imposed on that person under the Securities Act.